Top 10 Companies in the AI for Cancer Diagnosis Market (2026): Market Leaders Driving Global Healthcare Innovation

MARKET INSIGHTS

Global AI for Cancer Diagnosis market size was valued at USD 142.7 million in 2024. The market is projected to grow from USD 187.4 million in 2025 to USD 1.19 billion by 2034, exhibiting a CAGR of 30.1% during the forecast period.

AI for cancer diagnosis refers to artificial intelligence systems that analyze medical imaging and patient data to detect malignancies with high accuracy. These solutions leverage deep learning algorithms trained on vast datasets of radiology scans, pathology slides, and genomic information to identify patterns indicative of various cancers including breast, lung, prostate and others. Key technologies include computer‑aided detection (CAD) systems, machine learning models for risk assessment, and predictive analytics platforms.

The market growth is driven by increasing cancer prevalence, with WHO reporting 20 million new cases globally in 2024, alongside severe radiologist shortages. While North America currently dominates adoption due to advanced healthcare infrastructure, Asia‑Pacific shows the fastest growth as governments invest in AI healthcare initiatives. Recent FDA approvals for AI diagnostic tools, like those from Lunit and Paige AI in early 2024, demonstrate accelerating regulatory acceptance of these technologies in clinical settings.

AI for Cancer Diagnosis Market – View in Detailed Research Report

🔟 1. Lunit Inc

Headquarters: Seoul, South Korea
Key Offering: AI‑powered imaging analytics for breast and lung cancer detection

Lunit’s flagship product, Lunit INSIGHT, uses deep learning to analyze mammograms and chest CT scans, providing radiologists with rapid, high‑precision nodule detection and risk scoring. The platform has received FDA clearance and is integrated into over 2,000 hospitals worldwide.

Sustainability Initiatives:

• Data‑efficient models reducing computational carbon footprint
• Partnerships with global cancer registries to improve data diversity
• Commitment to ISO 14001 environmental management

🔟 2. Infervision

Headquarters: Shanghai, China
Key Offering: AI‑driven lung cancer screening and segmentation solutions

Infervision’s AI platform, LungAI, automates lung nodule detection on low‑dose CT scans, achieving sensitivity comparable to expert radiologists. The company has secured CE marking and is expanding into breast and head‑and‑neck oncology.

Sustainability Initiatives:

• Cloud‑based inference reducing on‑premise hardware energy use
• Collaboration with national health ministries to standardize AI protocols
• Investment in green data centers

🔟 3. Kheiron Medical

Headquarters: London, United Kingdom
Key Offering: AI‑assisted breast cancer screening and pathology analysis

Kheiron’s AI4ALL platform delivers automated breast cancer risk assessment and mammogram interpretation, with FDA clearance for use in screening programs. The company also offers AI‑enhanced histopathology analysis for colorectal and prostate cancers.

Sustainability Initiatives:

• Optimized inference engines reducing GPU consumption
• Open‑source data sharing to promote transparency
• Participation in the AI for Health partnership to improve equitable access

🔟 4. Shukun Technology

Headquarters: Beijing, China
Key Offering: AI‑powered diagnostic solutions for breast, lung, and prostate cancers

Shukun’s AI platform combines computer vision and deep learning to provide rapid, accurate imaging analysis across multiple modalities. The company has received FDA clearance for its breast cancer detection module and is actively expanding into other oncology indications.

Sustainability Initiatives:

• Development of lightweight models for edge deployment
• Data privacy compliance with GDPR and China’s AI regulations
• Green AI research initiatives funded by national grants

🔟 5. Niramai Health Analytix

Headquarters: Bangalore, India
Key Offering: Thermal imaging‑based breast cancer screening platform

Niramai’s m-Detect™ uses deep learning on thermal images to detect breast cancer without radiation, offering a non‑invasive screening option in resource‑constrained settings. The solution has received FDA clearance and is deployed across India’s public health network.

Sustainability Initiatives:

• Zero‑radiation screening reducing patient exposure
• Low‑power thermal sensors enabling mobile deployment
• Community outreach programs to raise screening awareness

🔟 6. Ibex Medical Analytics

Headquarters: Tel Aviv, Israel
Key Offering: AI‑enhanced pathology for prostate cancer and other solid tumours

Ibex’s AI‑driven pathology platform analyzes digitised slides to provide tumour grading, biomarker identification, and prognostic insights. The company has achieved FDA clearance for its prostate cancer module and partners with leading academic centres for multi‑modal research.

Sustainability Initiatives:

• Cloud‑native architecture reducing on‑premise hardware
• Data anonymisation protocols to protect patient privacy
• Collaboration with the Israeli Ministry of Health on AI policy

🔟 7. Oncora Medical

Headquarters: New York, United States
Key Offering: AI‑assisted oncology decision support for breast, lung, and prostate cancers

Oncora’s platform integrates imaging, genomics, and clinical data to generate personalised treatment recommendations. The solution is FDA‑cleared for use in clinical trials and has been adopted by several leading oncology centres.

Sustainability Initiatives:

• Optimised AI models to reduce inference energy
• Partnerships with academic institutions for open‑source research
• Support for tele‑oncology programmes in underserved regions

🔟 8. Imagene AI

Headquarters: Tel Aviv, Israel
Key Offering: AI‑based pathology and imaging analytics for solid tumours

Imagene’s platform uses deep learning to interpret histopathology slides and imaging studies, providing diagnostic support for a wide range of cancers. The company has secured FDA clearance for its breast cancer module and is expanding into colorectal and lung oncology.

Sustainability Initiatives:

• Energy‑efficient inference pipelines for large‑scale slide analysis
• Data‑privacy‑first approach with robust encryption
• Community‑based training programmes for pathologists

🔟 9. SkinVision

Headquarters: Amsterdam, Netherlands
Key Offering: AI‑driven dermatology screening for skin cancers

SkinVision’s mobile app uses deep learning to analyse skin lesions and provide risk scores for melanoma and other skin cancers. The solution is FDA‑cleared and is widely used by dermatology practices worldwide.

Sustainability Initiatives:

• Mobile‑first design reducing server load
• Data‑sharing agreements to improve model robustness
• Global outreach to increase early detection in low‑income regions

🔟 10. Xilis

Headquarters: New York, United States
Key Offering: AI‑powered diagnostic platform for lung, breast, and prostate cancers

Xilis’s X-Insight platform combines imaging and genomic data to deliver early cancer detection and risk stratification. The platform has achieved FDA clearance and is integrated into major oncology networks.

Sustainability Initiatives:

• Efficient model architecture reducing GPU usage
• Partnerships with research institutions for continuous improvement
• Focus on reducing diagnostic disparities through equitable AI deployment

Download FREE Sample Report: AI for Cancer Diagnosis Market – View in Detailed Research Report

AI for Cancer Diagnosis Market – View in Detailed Research Report

OUTLOOK

By 2034, the AI for Cancer Diagnosis market is projected to reach USD 1.19 billion, driven by expanding clinical adoption, regulatory streamlining, and the integration of AI into precision oncology workflows. The market will witness increased consolidation as larger incumbents acquire niche AI startups, fostering a more mature ecosystem.

FUTURE TRENDS

• Expansion of AI into rare cancers and multi‑modal diagnostics.
• Integration of AI with genomic profiling for personalised therapy selection.
• Growth of point‑of‑care AI devices enabling remote screening.
• Enhanced explainability of AI models to build clinician trust.
• Regulatory frameworks evolving to support AI‑driven clinical trials.